Get the Stockscreener App
0.4349
9.40%
-0.0451
After Hours:
.43
-0.0049
-1.13%
Calidi Biotherapeutics Inc stock is traded at $0.4349, with a volume of 180.46K.
It is down -9.40% in the last 24 hours and down -12.34% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$0.48
Open:
$0.4888
24h Volume:
180.46K
Relative Volume:
0.17
Market Cap:
$15.70M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-0.5903
EPS:
-0.7368
Net Cash Flow:
-
1W Performance:
-11.95%
1M Performance:
-12.34%
6M Performance:
-70.01%
1Y Performance:
-79.29%
1-Day Range:
$0.4303
$0.4945
1-Week Range:
$0.4303
$0.5098
52-Week Range:
$0.35
$4.90
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.4349 | 15.70M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World
Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX
Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus
Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire
Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan
Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan
Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa
Zealand names former Lilly exec Singh as CSO - biocentury.com
Calidi Biotherapeutics appoints new CEO - Investing.com
Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus
Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks
Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView
Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire
New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire
Cancer Breakthrough Alert: Top Oncologist Reveals New FDA-Cleared Stem Cell Therapy Development - Stock Titan
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors - The Manila Times
FDA Green Lights Revolutionary Cancer Treatment: Stem Cells Combined With Virus to Fight Multiple Tumors - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis - GlobeNewswire
Cancer Drug Developer Calidi Bio Strengthens Leadership: Renowned Oncologist Takes CMO Role - Stock Titan
Calidi Biotherapeutics Appoints New Chief Medical Officer - TipRanks
CLDI stock touches 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
CLDI stock touches 52-week low at $0.42 amid market challenges - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times
Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan
Calidi Biotherapeutics Cuts Losses by 50% While Expanding Cancer Gene Therapy Trials - Stock Titan
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com India
Virtu Financial LLC Buys Shares of 73,448 Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering - MSN
Calidi prices 3.33M shares at 65c in registered direct offering - TipRanks
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
Calidi Bio Secures Strategic $3.9M Investment to Accelerate Cancer Immunotherapy Pipeline - Stock Titan
Calidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent Glioma - Nasdaq
Calidi Biotherapeutics and City of Hope Provide Update on a - GlobeNewswire
Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma - MarketScreener
Breakthrough Brain Cancer Treatment Advances: 14 Patients Successfully Treated in Groundbreaking Trial - Stock Titan
CLDI stock touches 52-week low at $0.73 amid market challenges - MSN
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat
IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform - Yahoo Finance
Calidi’s Rtnova platform delivers transient gene therapy payloads to tumors - BioWorld Online
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.24%
Cap:
|
Volume (24h):